JP2018527932A - ＣＤ８＋ＣＤ４５ＲＣｌｏｗ Ｔｒｅｇの新しい亜集団およびその使用 - Google Patents

ＣＤ８＋ＣＤ４５ＲＣｌｏｗ Ｔｒｅｇの新しい亜集団およびその使用 Download PDF

Info

Publication number
JP2018527932A
JP2018527932A JP2018511706A JP2018511706A JP2018527932A JP 2018527932 A JP2018527932 A JP 2018527932A JP 2018511706 A JP2018511706 A JP 2018511706A JP 2018511706 A JP2018511706 A JP 2018511706A JP 2018527932 A JP2018527932 A JP 2018527932A
Authority
JP
Japan
Prior art keywords
human
cells
ifnγ
cd45rc low
treg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018511706A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018527932A5 (enExample
Inventor
ギヨンノー，キャロル
アネゴン，イグナシオ
ベジエ，セヴェリーヌ
Original Assignee
インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル）
インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル）
ユニバーシティ デ ナント
ユニバーシティ デ ナント
センター ホスピタリア ユニバーシタイア デ ナント
センター ホスピタリア ユニバーシタイア デ ナント
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル）, インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル）, ユニバーシティ デ ナント, ユニバーシティ デ ナント, センター ホスピタリア ユニバーシタイア デ ナント, センター ホスピタリア ユニバーシタイア デ ナント filed Critical インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル）
Publication of JP2018527932A publication Critical patent/JP2018527932A/ja
Publication of JP2018527932A5 publication Critical patent/JP2018527932A5/ja
Priority to JP2021133065A priority Critical patent/JP7254128B2/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2018511706A 2015-09-07 2016-09-06 ＣＤ８＋ＣＤ４５ＲＣｌｏｗ Ｔｒｅｇの新しい亜集団およびその使用 Pending JP2018527932A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021133065A JP7254128B2 (ja) 2015-09-07 2021-08-18 ＣＤ８＋ＣＤ４５ＲＣｌｏｗ Ｔｒｅｇの新しい亜集団およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15306366 2015-09-07
EP15306366.4 2015-09-07
PCT/EP2016/070991 WO2017042170A1 (en) 2015-09-07 2016-09-06 A new subpopulation of cd8+cd45rclow tregs and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021133065A Division JP7254128B2 (ja) 2015-09-07 2021-08-18 ＣＤ８＋ＣＤ４５ＲＣｌｏｗ Ｔｒｅｇの新しい亜集団およびその使用

Publications (2)

Publication Number Publication Date
JP2018527932A true JP2018527932A (ja) 2018-09-27
JP2018527932A5 JP2018527932A5 (enExample) 2019-09-26

Family

ID=54196910

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018511706A Pending JP2018527932A (ja) 2015-09-07 2016-09-06 ＣＤ８＋ＣＤ４５ＲＣｌｏｗ Ｔｒｅｇの新しい亜集団およびその使用
JP2021133065A Active JP7254128B2 (ja) 2015-09-07 2021-08-18 ＣＤ８＋ＣＤ４５ＲＣｌｏｗ Ｔｒｅｇの新しい亜集団およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021133065A Active JP7254128B2 (ja) 2015-09-07 2021-08-18 ＣＤ８＋ＣＤ４５ＲＣｌｏｗ Ｔｒｅｇの新しい亜集団およびその使用

Country Status (13)

Country Link
US (1) US20180251731A1 (enExample)
EP (1) EP3347452B1 (enExample)
JP (2) JP2018527932A (enExample)
KR (1) KR102768442B1 (enExample)
CN (1) CN108291203A (enExample)
AU (1) AU2016318762B2 (enExample)
BR (1) BR112018004454A2 (enExample)
CA (1) CA2997646C (enExample)
ES (1) ES2890818T3 (enExample)
IL (1) IL257891B (enExample)
MX (1) MX390494B (enExample)
WO (1) WO2017042170A1 (enExample)
ZA (1) ZA201801265B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022516408A (ja) * 2018-12-14 2022-02-28 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 単離されたＭＨＣ由来ヒトペプチドおよびＣＤ８＋ＣＤ４５ＲＣｌｏｗＴｒｅｇの抑制機能を刺激し、かつ活性化するためのその使用

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3042179A1 (en) * 2016-10-31 2018-05-03 Seattle Children's Hospital (dba Seattle Children's Research Institute) Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogenous foxp3 gene
CN118662615A (zh) 2017-03-15 2024-09-20 浩康生物系统公司 用于造血干细胞移植的组合物和方法
EP3652306A1 (en) * 2017-07-13 2020-05-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for increasing expansion and immunosuppressive capacity of a population of cd8+cd45rclow/-tregs
CN111684061B (zh) 2018-01-19 2024-07-30 美天施生物科技有限两合公司 表达嵌合抗原受体的调节性t细胞
ES3012854T3 (en) 2018-02-08 2025-04-10 Univ Leland Stanford Junior Allogenic hematopoietic stem cell transplantation
US11141435B2 (en) * 2018-03-14 2021-10-12 Thermogenesis Corporation Buoyancy-activated cell sorting (BACS)-compatible activation/transduction systems and methods
WO2020102503A2 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for t cell delivery
EP3963053A4 (en) * 2019-04-30 2023-01-18 The Regents of the University of California PEARL-FREE EX-VIVO EXPANSION OF HUMAN REGULATORY T-CELLS
EP4013780A4 (en) * 2019-08-14 2024-04-10 The Regents Of The University Of California CAR-T CELLS SPECIFIC FOR MODIFIED PROTEINS IN EXTRACELLULAR SPACES
US20230147657A1 (en) * 2020-03-20 2023-05-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Chimeric antigen receptor specific for human cd45rc and uses thereof
WO2024028486A1 (en) * 2022-08-04 2024-02-08 Nantes Universite In vitro method for obtaining clinical-grade cd8+ cd45rclow/- regulatory t cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003530101A (ja) * 2000-04-11 2003-10-14 ユニバーシティ・オブ・サザン・カリフォルニア 抑制性Ｔ細胞を誘導するためにＴＧＦ−βを用いる移植拒絶反応を防止する方法
US20100135974A1 (en) * 2007-01-31 2010-06-03 Yeda Research And Development Co. Ltd. Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10137181B2 (en) * 2014-04-01 2018-11-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Isolated donor MHC-derived peptide and uses thereof
JP6769948B2 (ja) * 2014-07-17 2020-10-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 移植拒絶の予防及び自己免疫疾患の治療に使用するための単離されたインターロイキン−３４ポリペプチド

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003530101A (ja) * 2000-04-11 2003-10-14 ユニバーシティ・オブ・サザン・カリフォルニア 抑制性Ｔ細胞を誘導するためにＴＧＦ−βを用いる移植拒絶反応を防止する方法
US20100135974A1 (en) * 2007-01-31 2010-06-03 Yeda Research And Development Co. Ltd. Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GUILLONNEAU C. ET AL.: "CD40Ig treatment results in allograft acceptance mediated by CD8+CD45RClow T cells, IFN-γ, and indo", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 117, no. 4, JPN6020020438, April 2007 (2007-04-01), pages 1096 - 1106, ISSN: 0004487134 *
LI X. L. ET AL.: "Mechanism and localization of CD8 regulatory T cells in a heart transplant model of tolerance.' , ,", THE JOURNAL OF IMMUNOLOGY, vol. 185, no. 2, JPN6020020439, 15 July 2010 (2010-07-15), pages 823 - 833, ISSN: 0004286706 *
ORDONEZ L. ET AL.: "A higher risk of acute rejection of human kidney allografts can be predicted from the level of CD45R", PLOS ONE, vol. 8, no. 7, JPN6020020441, July 2013 (2013-07-01), pages 69791, ISSN: 0004286707 *
XYSTRAKIS E. ET AL.: "Functional and genetic analysis of two CD8 T cell subsets defined by the level of CD45RC expression", THE JOURNAL OF IMMUNOLOGY, vol. 173, no. 5, JPN6020020443, 2004, pages 3140 - 3147, ISSN: 0004286708 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022516408A (ja) * 2018-12-14 2022-02-28 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 単離されたＭＨＣ由来ヒトペプチドおよびＣＤ８＋ＣＤ４５ＲＣｌｏｗＴｒｅｇの抑制機能を刺激し、かつ活性化するためのその使用
JP7609775B2 (ja) 2018-12-14 2025-01-07 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 単離されたＭＨＣ由来ヒトペプチドおよびＣＤ８＋ＣＤ４５ＲＣｌｏｗＴｒｅｇの抑制機能を刺激し、かつ活性化するためのその使用

Also Published As

Publication number Publication date
MX2018002849A (es) 2018-09-05
AU2016318762A1 (en) 2018-03-22
ES2890818T3 (es) 2022-01-24
KR20180054663A (ko) 2018-05-24
IL257891B (en) 2020-09-30
JP7254128B2 (ja) 2023-04-07
BR112018004454A2 (pt) 2018-09-25
AU2016318762B2 (en) 2022-03-31
EP3347452A1 (en) 2018-07-18
NZ740225A (en) 2025-05-30
RU2018107363A (ru) 2019-10-09
US20180251731A1 (en) 2018-09-06
RU2018107363A3 (enExample) 2020-02-27
RU2766691C2 (ru) 2022-03-15
WO2017042170A1 (en) 2017-03-16
ZA201801265B (en) 2022-08-31
IL257891A (en) 2018-05-31
EP3347452B1 (en) 2021-06-23
KR102768442B1 (ko) 2025-02-17
JP2021183631A (ja) 2021-12-02
CA2997646C (en) 2024-04-23
CN108291203A (zh) 2018-07-17
MX390494B (es) 2025-03-20
CA2997646A1 (en) 2017-03-16

Similar Documents

Publication Publication Date Title
JP7254128B2 (ja) ＣＤ８＋ＣＤ４５ＲＣｌｏｗ Ｔｒｅｇの新しい亜集団およびその使用
Ferri et al. A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis
US8053235B2 (en) Methods of generating antigen-specific CD4+CD25+regulatory T cells, compositions and methods of use
ES2686593T3 (es) Expresión de CD127 que correlaciona inversamente con FoxP3 y la función supresora de Treg CD4+
JP2017148042A (ja) Ｉｌ−１３産生ｔｒ１−様細胞及びその使用
JP2016192970A (ja) Ｔｒ１細胞を単離する新規な方法
US20210147801A1 (en) Methods for increasing expansion and immunosuppressive capacity of a population of cd8+cd45rclow/- tregs
RU2766691C9 (ru) НОВАЯ СУБПОПУЛЯЦИЯ CD8+CD45RClow КЛЕТОК TREG И ЕЕ ПРИМЕНЕНИЯ
EP3178487A1 (en) A method for obtaining hematopoetic cell population containing regulatory t cells (tregs) specific for an irrelevant antigen

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190815

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190815

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200616

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201113

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210420